Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study

Karachaliou, N.Cardona Zorrilla, A.Rodriguez-Abreu, D.Cobo Dols, M.Reguart Aransay, N.Viteri, S.Codony-Servat, J.Molina-Vila, M. A.D'Hondt, E.Rosell, R.2025-01-072025-01-072018-04-011556-0864https://hdl.handle.net/10668/24379enAfatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL studyconference outputopen access10.1016/S1556-0864(18)30471-41556-1380http://www.jto.org/article/S1556086418304714/pdf436557600192